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Pharmacy Practice
David B. Brushwood, R.Ph., J.D.*
INTRODUCTION
The widespread and growing use of pharmaceutical products
as a favored therapeutic modality in modern health care poses
significant challenges for the pharmacy profession. Traditionally
viewed as guardians of the nation's supply of medically useful
drugs, the responsibilities of pharmacists are expanding because
of the rapidly increasing volume of prescription orders,' and
also because of the heightened demand for expanded pharma-
cist services in drug therapy monitoring. 2 Pharmacists are re-
sponsible for assuring absolute accuracy in their traditional
dispensing role. This standard of perfection is an unreachable
benchmark for any system of service or product provision, but
pharmacists must nonetheless strive to achieve this ideal goal by
initiating "sufficient institutional controls" over their order
processing practices.' In addition, pharmacists have increasingly
been held to have a "duty to warn" when the special circum-
* Professor of Pharmacy Health Care Administration, The University of Florida
College of Pharmacy. This article is based on remarks presented at the Loyola Uni-
versity Institute for Health Law, April 12, 2000.
1. According to the National Association of Chain Drug Stores, the volume of
prescriptions filled by the nation's pharmacists rose from 2.0 billion in 1992 to 3.15
billion in 2000. National Association of Chain Drug Stores, Industry Facts, at http://
www.nacds.org/industry/industry-fr.html (last visited Mar. 21, 2001).
2. A report issued in December, 2000 by the United States Department of Health
and Human Services indicates that the supply of pharmacists needed for the delivery
of quality health care is being strained by the sharp demand for pharmacist services.
Press Release, U.S Department of Health and Human Services, Health Resources
and Services Administration, HHS Report Finds Emerging Shortage of Licensed
Pharmacists (Dec. 12, 2000), available at www.hrsa.gov.newsroom/releases/2000Re-
leases/pharmacistshortage.html. The report concludes that the number of unfilled
pharmacist positions nationally rose sharply from about 2,700 in February of 1998 to
nearly 7,000 in February of 2000, and that such vacancies are expected to continue to
grow. Id.
3. Primary liability of pharmacies for failure to "initiate sufficient institutional
controls" over the practice of their pharmacists was first recognized in Harco Drugs,
Inc. v. Holloway, 699 So.2d 878, 881 (Ala. 1995). This new exposure to corporate
liability, added to the traditional corporate exposure to secondary liability under re-
spondeat superior, requires that pharmacies create practice sites that are conducive to
successful pharmacy practice. Pharmacists can produce good results from their prac-
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stances of a prescription suggest to a pharmacist that a patient
may be at risk in a way that either the patient or the prescribing
physician may not appreciate.4 Pharmacists are being asked to
do more for each patient, and there are more patients whose
needs pharmacists are being asked to meet.
Owing to the increasing complexity of modern pharmacother-
apy, and to the uniform adoption of the clinically-oriented
Pharm.D. degree, contemporary pharmacists find themselves
facing an unprecedented window of opportunity, during which
the practice of "pharmaceutical care" could finally become a re-
ality.5 Conceived as a complement to medical care and nursing
care, the purpose of pharmaceutical care is to address the well-
documented problem of preventable drug-related morbidity.6
The value of reliance on those pharmacists who practice phar-
maceutical care to promote good outcomes for patients and to
prevent adverse drug effects has been empirically established.7
tices only if pharmacies provide a supportive place to practice, within which systems
work well to enable pharmacists to meet societal expectations of them.
4. Although there continues to be controversy over a general duty for pharmacists
to provide warnings to patients of all relevant potential adverse drug effects, it has
become well settled that when a pharmacist has actual knowledge of an existing prob-
lem with drug therapy, and when harm to a patient is reasonably foreseeable, the
pharmacist has a duty to inform the patient of actions that can be taken to eliminate
or minimize the risk of harm. See, e.g., Dora A. Gonzalez, Prescription for Litigation:
In Pursuit of the Pharmacist's "Duty to Warn" of Adverse Effects of Prescription
Drugs, 1 J. LEGAL ADVOC. & PRAc. 53 (1999); Roseann B. Termini, The Pharmacist
Duty to Warn Revisited: The Changing Role of Pharmacy in Health Care and the Re-
sultant Impact on the Obligation of a Pharmacist to Warn, 24 OHIo N. U. L. REV. 551
(1998).
5. See, e.g., Charles D. Hepler & Linda M. Strand, Opportunities and Responsibili-
ties in Pharmaceutical Care, 47 AM. J. Hosp. PHARM. 533 (1990); L. M. Posey, Phar-
maceutical Care: Will Pharmacy Incorporate Its Philosophy Of Practice?, 37 J. AM.
PHARM. Ass'N. 145 (1997) (discussing the expanding role of pharmacists in patient
care issues and how pharmacists can approach these issues).
6. Although some medication-related problems are simply tragic but unavoidable
costs of therapeutic advances that bring previously unimaginable value to patient
care, other medication-related problems are completely preventable by system
changes that adapt to the increasing complexity of pharmacotherapy. S. Hennessy,
Potentially Remediable Features of the Medication-Use Environment in the United
States, 57 AM. J. HEALTH-SYS. PHARM. 543 (2000).
7. T-J Grainger-Rousseau et al., Therapeutic Outcomes Monitoring: Application
of Pharmaceutical Care Guidelines to Community Pharmacy, 37 J. AM. PHARM.
ASS'N. 647 (1997) (concluding that pharmacists can successfully implement drug ther-
apy management in their practices, overcoming may obstacles to doing so); see also L.
R. Borgsdorf et al., Pharmacist-Managed Medication Review in a Managed Care Sys-
tem, 51 AM. J. Hosp. PHARM. 772 (1994) (describing a pharmacist-managed medica-
tion review program that produced savings of $644 per patient per year due to
reductions in the numbers of unscheduled physician visits, urgent care visits, emer-
gency room visits, and hospital stays); V. M. Wilt et al., Outcome Analysis of a Phar-
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Yet, despite obvious advantages over the traditional product-
oriented focus of dispensing pharmacists, this new patient-cen-
tered approach to pharmacy practice has been slow to evolve.
Time constraints faced by pharmacists, information deficits con-
cerning specific patients and their unique needs, and the limits
of the physical settings in which pharmacists practice, pose sig-
nificant barriers to the maturation of pharmaceutical care from
academic theory to practice reality.8 There is a very real possibil-
ity that the logistics of traditional health care will prevent phar-
macists from re-professionalizing to accept responsibility for the
outcomes of drug therapy.
Internet pharmacy has the potential to overcome barriers that
exist within traditional pharmacy practice, thereby enabling suc-
cess with pharmaceutical care. Through alliances between local
pharmacies and their Internet-based partners, prescription order
processing can be moved offsite to "central fill" locations, re-
ducing the volume of prescription orders to process at local
pharmacies. Routine questions about medications can be an-
swered by online pharmacists using email or other electronic
(eventually real-time video) connections with patients, further
addressing the current workload constraints that exist at most
local pharmacies. Knowledge of a patient's diagnosis, results of
laboratory tests, and established drug monitoring parameters,
largely unavailable to pharmacists at present, can be made ac-
cessible to local pharmacists through the Internet. Pharmacies
macist-Managed Anticoagulation Service, 15 PHARMACOTHERAPY 732 (1995)
(describing a potential cost avoidance of $4,072.68 per person per year in a family
practice setting when pharmacists manage drug therapy for improved outcomes of
patients receiving warfarin therapy). The focus of these reports has primarily been on
economic cost savings for managed care plans, but the human cost savings are per-
haps equally as dramatic, although far more difficult to quantify and report.
8. Although pharmacists in some practice settings have expanded their influence
into areas beyond accuracy in order processing, there is a lack of congruence between
the abilities of pharmacists and societal expectations of them. Paul G. Grussing, A
Comparison of Empirical Studies of Pharmacy Practice with Judicial Descriptions, 44
DRAKE L. REV. 483, 485 (1996) (noting that barriers to practice frustrate the phar-
macy profession's goal of serving society). Judicial perspectives on pharmacy practice
have slowly evolved from concern for the limits of retail-oriented practice environ-
ments to optimism that pharmacists may be able to overcome environmental barriers
to expanded practice. Scholarly discourse has encouraged a judicial view that ex-
pands expectations of pharmacists. See R. Paul Asbury, Pharmacist Liability: The
Doors of Litigation Are Opening, 40 SANTA CLARA L. REV. 907 (2000) (concluding
that traditional stereotypes of pharmacists are no longer accurate and that courts
should abandon the limits of liability traditionally afforded pharmacists); Edward
Casmere, Rx for Liability: Advocating the Elimination of the Pharmacist's No Duty to
Warn Rule, 33 J. MARSHALL L. REV. 425 (2000) (suggesting that a no duty to warn
rule prevents pharmacists from achieving the professional recognition they deserve).
2001]
3
Brushwood: Responsive Regulation of Internet Pharmacy Practice
Published by LAW eCommons, 2001
Annals of Health Law
and pharmacists can use the Internet to integrate themselves
with other care providers and institutions, opening up new op-
portunities for public service that simply cannot occur in the
current disconnected system that locks pharmacists out of the
mainstream of health care.9
This article suggests that pharmacy regulators could best pro-
tect and promote the public health through responsive Internet
regulation that facilitates expanded pharmaceutical care prac-
tices. Regulation of Internet pharmacy should avoid restrictions
that inhibit direct online care and product provision by pharma-
cists. Tough regulation directed toward Internet-based "rogue
pharmacies" runs the risk of replicating the "war on drugs" that
has for many years been fought by the Drug Enforcement Ad-
ministration and other law enforcement agencies with only mod-
est success. This crusade to protect the public from the scourge
of drug addiction has prevented the diversion of many narcotic
controlled substances, but it has also had the unintended, yet
foreseeable effect of decreasing access to appropriate analgesic
medications, leading to uncontrolled pain for many patients.10
Tough regulation of Internet pharmacy could similarly restrict
beneficial pharmaceutical care activities if regulations were so
broad in scope and uncompromising in application as to have a
"chilling" effect on even the most well intentioned of providers.
Most pharmacists are highly risk averse. They adopt practices
that steer them far clear of regulatory violations, and the threat
of even an accusation of impropriety is often sufficient to alter
practice patterns.1 With regard to Internet pharmacy, the chal-
lenge pharmacy regulators must meet is to develop a regulatory
9. D. M. Angaran, Telemedicine and Telepharmacy: Current Status and Future Im-
plications, 56 AM. J. HEALTH-SYS. PHARM. 1405 (1999) (suggesting that telepharmacy
presents the pharmacy profession and individual pharmacists with great opportunities
to become an even more integral part of the medication-use system).
10. See R. T. Angarola & S. D. Wray, Legal Impediments to Cancer Pain Treat-
ment, 2 ADVANCES IN CANCER PAIN MANAGEMENT AND THERAPY 213 (1989) (not-
ing that drug statutes and regulations often have a chilling effect on the prescribing
and dispensing of opiates). The problems caused by underuse of opioid analgesics
have been addressed through changes in policy that encourage appropriate pain man-
agement. See D. E. Joranson and A. M. Gilson, State Intractable Pain Policy: Current
Status, APS BULLETIN 7 (Mar./Apr., 1997) (documenting a trend toward greater toler-
ance by regulators of opioid use in intractable pain). However, policy-on-paper has
not necessarily changed policy-in-practice.
11. See R. Sean Morrison et al., "We Don't Carry That"- Failure of Pharmacies
in Predominantly Nonwhite Neighborhoods to Stock Opioid Analgesics, 342 NEW
ENG. J. MED. 1023 (2000) (reporting that of pharmacies surveyed in the New York
City area, 51% did not have in stock a sufficient supply of opioid medications to
provide adequate treatment for a patient with severe pain).
[Vol. 10
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approach that is designed to prevent inappropriately risky medi-
cation use, while leaving unaffected the online innovations that
can enhance the appropriate use of medications and improve a
patient's quality of life.
Part I of this article describes established principles of drug
regulation, and it explains how those principles can be applied
to Internet pharmacy. 12 In Part II, the potential hazards of over-
regulation are reviewed.13 Outcomes-oriented responsive regu-
lation is described as an emerging trend, and opportunities are
noted for use of the Internet to improve outcomes for patients.
Part III criticizes state paternalism, if it restricts informed pa-
tient choice of a provider of pharmaceutical products and ser-
vices.' 4 This article concludes that the most appropriate method
for regulation of Internet pharmacy, in fact the only method that
has a reasonable chance of success, is the Verified Internet Phar-
macy Practice Site ("VIPPS") program of the National Associa-
tion of Boards of Pharmacy ("NABP"). 5
I. STATE AND FEDERAL REGULATION OF PHARMACY
Pharmacists are required to comply with federal laws relating
to the distribution of drug products.1 6 Once a drug has enter
interstate commerce, any person subsequently holding it for sale
must be in compliance with both the Federal Food, Drug and
Cosmetic Act ("FDCA") 17 and the Controlled Substances Act
("CSA"). 18 Pharmacists must also comply with state laws regu-
12. Infra Part I (discussing the principles of drug regulation and how these princi-
ples can be applied to Internet pharmacy).
13. Infra Part II (reviewing the dangers of over regulation).
14. Infra Part III.A (criticizing state paternalism as a restriction on informed pa-
tient choice).
15. Infra Part III.C (concluding that the most appropriate method for regulation
of Internet pharmacy is the VIPPS program of the NABP).
16. United States v. Sullivan, 332 U.S. 689, 696 (1948) (holding that the act of
dispensing by a pharmacist is an act in interstate commerce and is subject to the mis-
branding provisions of the federal Food Drug and Cosmetic Act).
17. 21 U.S.C.A. §§ 301-397 (West 1999 and West Supp. 2000). The FDCA applies
to all drug products, and it is administered by the federal Food and Drug Administra-
tion ("FDA"). Through its administration of the FDCA, the FDA assures the safety
and efficacy of new drugs introduced into interstate commerce, it regulates the label-
ing and advertising of drugs, and it oversees the purity of drugs. FDA, Overview of the
Food and Drug Administration, at http://www.fda.gov/opacom/hpview.html (last vis-
ited Feb. 23, 2001) [hereinafter Overview of the Food and Drug Administration].
18. 21 U.S.C.A. §§ 801-971 (West 1999 and West Supp. 2000). The CSA applies
only to those drug products that have a potential for abuse, and it is administered by
the federal Drug Enforcement Administration ("DEA"). Through its enforcement of
the CSA, the DEA assures that abusable medications are restricted to a defined dis-
2001]
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lating the practice of the profession of pharmacy. In most states,
professional regulation of pharmacy is accomplished through a
pharmacy act in which the legislature creates and empowers a
board of pharmacy. The state board of pharmacy promulgates
rules and regulations, which it enforces along with the provi-
sions of the pharmacy act.
Internet pharmacy does not fit well into the standard regula-
tory scheme under which the federal government regulates the
drug product, while state government regulates the pharmacy
profession. Distinctions between product distribution and the
provision of professional services become blurred, and the sepa-
rate states or countries in which providers and recipients of ser-
vices are located make it difficult to know who, if anyone, has
jurisdiction over a transaction. Consider the following hypo-
thetical example: Using the Internet, a Florida patient orders
pharmaceutical products from an Internet site that purports to
be located in Texas and promotes online availability of prescrip-
tion-only medications without a prescription. In reality, the site
is linked from a Texas site to another site in Nevada, and the
patient never knows this. A questionnaire filled out by the pa-
tient is reviewed by a physician in Rhode Island, who receives
the patient's electronically submitted information from the site
in Nevada, and then authorizes the patient to receive the re-
quested prescription-only medication. An email message is then
sent to the patient by an Illinois pharmacy, offering to discuss
the medication with the patient if the patient has any questions.
This pharmacy includes in its message a hyperlink to a Louisiana
site that describes in detail how to use the prescription-only
medication, and the possible side effects of the medication. Sev-
eral days later, a parcel with a return address of a North Caro-
lina pharmacy arrives in Florida, and inside is a prescription vial
containing the medication, labeled with the name and address of
a different North Carolina pharmacy. If problems should arise
for the patient, it would be difficult to know what regulatory
authority has jurisdiction over the transaction. Even if substan-
tive law is clear, the procedure of enforcement is certain to be
time-consuming and unreliable.
The possible scenario described above is certainly not the only
way for an Internet pharmacy to operate; nor it is necessarily
typical of Internet pharmacies. There are some sites, many of
tribution system, and that those who divert controlled substances outside the system
are punished for their wrongdoing.
[Vol. 10
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them "offshore," that completely ignore the formality of requir-
ing a physician's authorization to dispense, and they readily ship
prescription-only medications to anyone who has the ability to
pay for them, without even the pretense of a physician-reviewed
questionnaire. On the other hand, the well-known dispensing-
only sites, many of which have developed alliances with large
community pharmacy chains, will meticulously follow all appli-
cable legal requirements, and will not provide prescription-only
products unless a patient has provided a valid prescription from
the patient's own physician. These varied ways of conducting an
Internet pharmacy business lead to differing needs of regulation
to protect the public health.
A. Applying The Law To Internet Pharmacy
The outright sale of prescription-only pharmaceuticals with-
out authorization from a licensed prescriber is the dispensing ac-
tivity that most clearly violates the FDCA. Under the FDCA, a
drug is classified as prescription-only for one of two reasons: (1)
either it is deemed unsafe for use except under the supervision
of a state-licensed prescriber, or (2) it is limited to prescription-
only use by its approved New Drug Application. 19 The act of
dispensing a drug contrary to this prescription requirement is an
act that results in the drug being deemed misbranded while held
for sale.2 ° Misbranding is a serious violation of the FDCA that
can result in seizure of a product, criminal prosecution of those
who have distributed it, and an injunction to prevent further dis-
tribution.21 Internet pharmacy sites that make no attempt to in-
volve a physician in an authorization to dispense prescription-
only medications are clearly in violation of the FDCA. They
have misbranded the product.
When a prescription-only drug is dispensed pursuant to a phy-
sician's authorization that results from the review of an online
questionnaire filled out by a patient, application of the FDCA is
not so straightforward. It has been suggested that when a physi-
cian prescribes based solely on the review of an electronic mes-
sage from a patient, there is legally not a "prescription," because
there is no legitimate physician-patient relationship and/or be-
cause a legal prescription results only when a physician has
19. 21 U.S.C.A. §§ 353, 355 (West 1999 and West Supp. 2000).
20. 21 U.S.C.A. § 353(b)(1) (West 1999 and West Supp. 2000).
21. 21 U.S.C.A. §§ 331-337 (West 1999).
2001]
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physically examined a patient.22 If this interpretation is correct,
then dispensing pursuant to an invalid physician's order would
constitute a misbranding violation as described above. How-
ever, this legal approach presents potential difficulties, because
in traditional prescribing there may not always be a physician-
patient relationship that meets these narrow legal standards.
Furthermore, problems might arise in the regulation of desirable
innovative approaches to telemedicine, where physicians and
patients may be remote from each other and not personally
known to each other, if regulators were to adopt a very narrow
construction of what physician behaviors are necessary to create
a legally sufficient prescription. Developing strict standards to
evaluate the conduct of physicians and patients, as a prerequi-
site to the recognition of a valid physician-patient relationship,
might be an approach that creates more problems than it solves.
Regulatory intrusion in the physician-patient relationship may
put a stop to inappropriate Internet pharmacy practices, but it
could also interfere with legitimate traditional health care or
with valuable innovation in medical practice.
The FDCA offers an alternative to the potentially restrictive
regulatory approach centered on defining the attributes of an
acceptable physician-patient relationship. Rather than creating
a new set of rules that requires an evaluation of the character of
a prescriber-patient relationship (a perilous and potentially con-
troversial activity), regulators could instead consider using ex-
isting statutory requirements that apply to those who dispense
under prescriptive authority resulting from a diagnosis made
through the mail. As is so often the case with the FDCA, this
requirement depends heavily on the misbranding provisions of
the Act. Under the FDCA, current misbranding provisions re-
quire extensive disclosure of information, at such a high level
that dispensers could not possibly comply. 3 Yet, dispensers es-
22. Ross D. Silverman, The Changing Face of Law and Medicine in the New Mil-
lennium, 26 AM. J.L. & MED. 255, 267 (2000) (describing a view held by some medical
groups that to prescribe a medication, the standard of medical care requires a physical
examination of the patient, dialogue with the patient to discuss treatment alternatives,
an attempt to establish a reliable medical history, information about the benefits and
risks of a prescribed medication, and follow-up to assess the therapeutic outcome).
23. 21 U.S.C.A. § 352(f) (West 1999). The misbranding provisions of this statu-
tory section require that the labeling of a drug bear "adequate directions for use," and
"such adequate warnings against use in those pathological conditions or by children
where its use may be dangerous to health." Id. FDA regulations interpreting these
requirements are summarized in 21 C.F.R. §§ 200-299 (2000). There is a strong argu-
ment that it would be impossible for a pharmacy to comply with the stringent pre-
[Vol. 10
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cape what would otherwise be a misbranding violation, through
a specific statutory exemption that relieves them of the need for
compliance with exhaustive information disclosure require-
ments. As long as their prescription vial is properly labeled with
the patient's name, prescriber's name and directions for use, ac-
cording to information provided in the prescription being filled,
they are eligible for the exemption. The FDCA states, however,
that the exemption from the extensive disclosure requirement
does not apply to "any drug dispensed in the course of the con-
duct of a business of dispensing drugs pursuant to a diagnosis by
mail. ' 24 Thus, an online pharmacy that conducts a business of
dispensing pursuant to diagnosis by email would lose the exemp-
tion, be forced to comply with extensive misbranding provisions
that cannot be met, and would therefore be in violation of the
misbranding section of the FDCA. This statutory provision is,
in effect, an exemption from an exemption. It does not apply
simply to the act of prescribing by mail, or even to occasional
acts of dispensing by mail. What is made illegal by the FDCA
under this provision is the conduct of a business that promotes
the availability of prescription-only drugs through diagnosis and
prescribing by electronic mail, and then dispenses prescription
drugs under such tenuous authority. Drugs dispensed in this
way are misbranded under the FDCA. Thus, no intrusive evalu-
ation of the physician-patient relationship is necessary. If email
is considered mail (not a huge stretch of the imagination), then
Internet pharmacies that conduct a business of dispensing medi-
cations prescribed through evaluation of electronic information
have violated the law.
The only online pharmaceutical dispensing practice that
clearly complies with the FDCA is the pharmacy practice that
insists on a patient presenting, in some way, a prescription is-
sued by the patient's local physician. In many ways, this phar-
macy practice model is merely an advanced version of mail-
service pharmacy. Over the Internet, such practices offer
quicker, more consistent, and more comprehensive service than
the service that can be provided through the mail. Although
somewhat controversial when they were introduced several de-
cades ago, quality concerns about mail-service pharmacies have
scription drug labeling regulations, because pharmacies dispense prescription drugs
directly to patients, and prescription drugs are necessarily those drugs that are incapa-
ble of being labeled for safe and effective use by persons who are not health care
professionals.
24. 21 U.S.C.A. § 353(b)(2) (West 1999 and West Supp. 2000).
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been resolved.25 This is an efficient and effective way to provide
pharmaceutical products to those patients whose drug therapy
monitoring services are furnished through another means. From
a regulatory perspective, there are no critical FDCA issues for
Internet pharmacies that function as mail-service pharmacies
have. These are state-licensed businesses. They are required to
be licensed in most states to which they ship dispensed pharma-
ceutical products, and they are subject to the same controls as
any pharmacy within the state to which pharmaceutical products
are dispensed. There is no evidence that these Internet pharma-
cies present threats to the public health that differ significantly
from those of any other state regulated pharmacy practice.
B. Enforcing The Law With Internet Pharmacies
The enforcement of pharmacy laws by state boards of phar-
macy and other state regulators faces obvious obstacles when an
allegedly dangerous Internet pharmacy practice is located out-
of-state. In the absence of evidence that an in-state pharmacy
poses a risk of harm to in-state patients, state pharmacy regula-
tors may have a difficult time justifying the use of resources for
the enforcement of state laws. When a patient in one state is
placed at risk of harm by a pharmacy in another state, regulators
in both states must cooperate for them to be effective in their
joint enforcement. Brick-and-mortar pharmacies can be investi-
gated through cooperative efforts of regulators in two states,
and problems with quality can be addressed in much the same
way as is done with in-state pharmacies. However, in the time it
takes to discover, investigate, and provide notice to an alleged
Internet pharmacy violator, the fast-paced entrepreneur respon-
sible for the original pharmacy site may very well have closed
that site and moved to a different Internet location. The ability
of businesses to link sites to each other makes it difficult for
regulators to know against whom enforcement action should be
initiated. Moving targets are hard to regulate, and the Internet
facilitates frequent moving.
Despite these practical difficulties, there have been high-pro-
file actions by attorneys general in several states to stop illegal
Internet pharmacy practice. These actions usually charge that
subject pharmacies have dispensed prescription drugs without a
license in the state. They may also charge a violation of state
25. See Gregory S. Munro, Regulation of Mail-Order Pharmacy, 12 J. LEGAL
MED. 1 (1991) (calling for state regulation of mail-order pharmacy).
[Vol. 10
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consumer fraud laws.26 As well-intended as these actions may
be, it remains to be seen whether state attorneys general can
maintain their level of commitment to this resource-intensive is-
sue. The results of the recent state actions are not encouraging.
One of the most active enforcers, Kansas Attorney General
Carla Stovall, has estimated that of 400 online pharmacies be-
lieved to be selling drugs in the United States, only six were op-
erating within the law, and only a fraction of the illegal
operators were being investigated by a government agency.27
Meanwhile, the chief investigator of unlicensed medical practice
in Florida disclosed that he had only two people to investigate
the entire health care industry.28 Given the national scope and
technical complexity of the problem, in the face of limited state
resources, it is not surprising that state regulators have turned to
federal authorities for help.
As the agency primarily responsible for regulating drug ap-
proval, production, distribution and marketing,29 the FDA finds
itself not particularly well situated to regulate professional prac-
tice. Yet, when the professional practice of pharmacy is used as
a charade to protect large scale drug distributors from federal
scrutiny, the FDA will not hesitate to weigh in with enforcement
of federal laws usually applied only to manufacturers. For ex-
ample, in the early 1990s, the FDA began to enforce federal
laws against massive compounding by a small number of high-
volume interstate distribution businesses that were masquerad-
ing as local pharmacies.30 The federal enforcement action oc-
curred only after state regulators were unable to protect the
public from what had become an unregulated industry of clan-
26. See Mail-Pharmacy Sues Michigan Over Attempt to Regulate Internet Drug
Sales, 5 MEALEY'S EMERGING DRUGS & DEVICES 6 (Feb. 17, 2000).
27. Sara Fritz, In U.S. No Easy Rx for Online Pharmacies, ST. PETERSBURG
TIMES, Apr. 2, 2000, at 1A.
28. Id.
29. Overview of the Food and Drug Administration, supra note 17.
30. See United States v. Baxter Healthcare Corp., 901 F.2d 1401 (7th Cir. 1990)
(concluding that the FDCA treats commercial manufacturers of drugs differently
from pharmacies, because an improperly manufactured drug produced on a large
scale will harm more patients than the same compounding mistake made on a smaller
scale); see also United States v. Sene X Eleemosynary Corp., 479 F.Supp. 970 (S.D.
Fla. 1979) (holding that the "practice of pharmacy defense" does not apply to a large
interstate compounding operation that bears none of the characteristics of a tradi-
tional pharmacy practice).
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destine drug manufacturers. An amendment to the FDCA was
necessary to define FDA's regulatory authority in this area.31
The FDA has begun a similar enforcement campaign against
Internet pharmacies, both foreign and domestic. However, the
issues are more complex than they were with compounding
pharmacies, and the targets of regulation are far more difficult
to find. Federal enforcement activities directed at Internet
pharmacy sites outside the United States have been of two
types: (1) direct action against providers to put them out of busi-
ness, in cooperation with local law enforcement authorities, and
(2) distribution of an Import Alert to customs inspectors, de-
signed to deny entry into the United States of illegal shipments
from offshore Internet pharmacies.32 Actions directed toward
domestic sites have been equally as determined, but far less pub-
lic. The agency has provided support for state enforcement ac-
tivities, and it has stressed the need for more stringent self-
regulation by the industry. Authority for federal enforcement
has been based primarily on a conclusion that Internet sites are
directed to the public, therefore strict rules for promotion of
drugs directly to consumers apply.33 Most Internet sites do not
comply with the rigid requirements for advertising of prescrip-
tion-only drugs directly to the public, thus they are considered in
violation of the FDCA. This is an indirect approach to regula-
tion that may be technically valid, but it uses statutory authority
that was clearly intended to address public health threats other
than those presented by Internet pharmacy. Meanwhile, the
agency waits for Congress to provide more specific statutory
direction.
Ultimately, no matter how tough state and federal regulators
may be toward Internet pharmacies, their efforts will fall short
of even the most modest goals. Just as illicit drug use has not
been significantly curtailed, because enforcement authorities
31. 21 U.S.C.A. § 353a (West 1999) (codifying the amendment and carving out a
safe harbor for pharmacies that compound small quantities of medications to meet
special needs of individual patients, pursuant to a prescription issued by the patients'
physicians), held unconstitutional by Western States Med. Ctr. v. Shalala, 2000 WL
33153172 (9th Cir.) (holding that § 353a is invalid in its entirety because § 353a(a) and
§ 353a(c)'s restrictions on commercial speech violate the First Amendment, but can-
not be severed from the rest of the provisions of § 353a).
32. See Robert Pear, U.S. and Thai Officials Attack Internet Sales of Medicine,
N.Y. TIMES, Mar. 21, 2000, at A18.
33. Marc J. Scheineson, Ready to Regulate, FDA Goes Online: Agency Has
Dropped Hands-Off Approach to Web Pharmacies, LEGAL TIMES, June 19, 2000, at
25.
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cannot be on every street corner, every hour, of every day, In-
ternet pharmacy regulators will discover that they cannot moni-
tor all web sites at all times. The decades-long failure of
narcotic drug control authorities to prevent importation of illicit
drugs into the country should instruct that the country's border
cannot be made secure from anything but a small number of
shipments made by offshore Internet sites to domestic medica-
tion users. And there is a terrible risk that strong regulation
would stifle the Internet's growth and innovation, while doing
little to prevent inappropriate medication use. Onerous In-
ternet pharmacy regulation could have the unintended effect of
deterring the development of novel approaches to care provi-
sion that reduce problems with drug therapy and enable alli-
ances that improve the quality of care.
II. THE COSTS OF OVER REGULATION
As noted above, there is clear evidence of a correlation be-
tween aggressive regulation of pharmacists and conservative
pharmacy practices that do not consistently meet the needs of
patients. Given the choice between a behavior that may raise a
regulatory red flag but is clearly beneficial to a patient and an
alternative behavior that is safe from a regulatory perspective
but may not provide all available benefits to patients, many risk-
averse pharmacists will adopt the latter strategy. 34 This is a so-
bering lesson learned through recognition of the barriers to ef-
fective pain management created by regulation of controlled
substance medications. The under-treatment of pain is a serous
problem in the American health care system, and one cause of
the problem is a perception that regulators are intolerant of in-
novative pain management practices that challenge traditional
notions of appropriate care.35 Even though recent changes in
policy-on-paper have clarified that restrictions on drug diversion
should not play any role in restrictions on patient care, policy-in-
practice has yet to reflect the more tolerant perspective of regu-
lators. Once the fear of regulatory action becomes ingrained in
the mind of a practitioner, it is difficult to dispel.
34. As recently as 1980, a DEA manual for pharmacists instructed that "[a] phar-
macist who has any doubts, whatever, concerning the legitimacy of a prescription or-
der presented to him should not dispense it." See Drug Enforcement Administration,
THE PHARMACIST'S MANUAL 34 (1980).
35. See Ann Alpers, Criminal Act or Palliative Care? Prosecutions Involving the
Care of the Dying, 26 J. L. MED. & ETHICS 308 (1998) (analyzing legal cases in which
health care providers have been prosecuted for overuse of controlled substances).
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Assertive and much-publicized enforcement directed against
Internet pharmacy sites has the potential to deter innovative In-
ternet pharmacy practices, in much the same way as aggressive
regulation directed at diversion of narcotics has deterred inno-
vative pain management practices. It is not always the reality of
enforcement that matters as much as it is the perception that
one is subject to enforcement action. Regulation is a powerful
positive tool that can enable practitioners to meet their respon-
sibilities to patients and improve outcomes for patients, but reg-
ulation can also prevent the development of new and valuable
approaches to practice. Long viewed as being separate from the
practice of health care and as a necessary evil to be tolerated but
not welcomed, health care regulation has recently experienced a
renaissance. Responsive regulation, as opposed to restrictive
regulation, has the potential to bring health care regulators into
the mainstream of health care. It is important that regulators of
Internet pharmacy recognize the need to be specific in their en-
forcement activities and responsive to needs of the health care
system. They must complement enforcement and discipline with
at least equal emphasis on activities geared toward enabling pro-
ductive change through regulation.
A. The Promise of Responsive Regulation
Responsive regulation promotes improvements in the quality
of care. The quality improvement function of responsive regula-
tion will be said to have succeeded when aggregated data mea-
suring the professional performance of a group of licensed
practitioners indicate that the mean for performance has
changed for the better in response to regulatory activities. Most
graphs illustrating the level of competence of a group of practi-
tioners will show there are two opposing "tails" on either side of
a bell-shaped curve plotting the number of practitioners versus
the competence of each individual practitioner. The vast major-
ity of practitioners will fall within the large body of the curve,
near the mean and just barely below or above either side of it.
The least competent practitioners will be represented in the low
"tail," and the most competent practitioners will be represented
in the high "tail" of the curve.
There are two types of regulatory actions that can significantly
increase the mean for the group, thus showing an improvement
in quality for the group. The first action is "culling." The elimi-
nation of truly incompetent practitioners from a group will raise
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the mean of the competency for the group. Slicing off the lower
"tail" of the curve shifts the curve in a positive direction, thus
elevating the mean of competence for the group. This is the
traditional role of the health care regulator. The second action,
an alternative to the traditional enforcement function, is really
an array of activities which emphasize removing systematic
threats to quality and introducing systematic incentives to qual-
ity. Regulation geared toward those practitioners at or near the
mean, and those at the higher "tail" of the curve can also shift
the curve in a positive direction, just as can culling. These ac-
tions have a greater potential to improve the overall compe-
tence of the group, because there are far more individual
practitioners near or above the mean than there are practition-
ers well below the mean. Yet, despite its potential for success,
apple "polishing" has not be used by regulators nearly as fre-
quently as has apple "picking." New theories of regulation sug-
gest that cautious culling is necessary but far from sufficient to
meet the regulatory challenge of public health protection.
Troyen Brennan and Donald Berwick have described a plan
for the implementation of responsive regulation to enable suc-
cess rather than punish failure. In their landmark book, New
Rules: Regulation, Markets, and the Quality of American Health
Care,36 Brennan and Berwick propose a systematic approach to
health care regulation, based on the principles of Continuous
Quality Improvement ("CQI"). Their plan for responsive regu-
lation encourages risk-taking as long as risks are monitored and
controlled. They suggest that safe harbors from regulation
should be carved out for major innovation, and that successful
innovation should be rapidly spread throughout the health care
system through the use of regulatory incentives. 37 They contend
it is anachronistic to regulate fragments in an era when the pri-
mary goal is to reconnect the parts into a whole.
In a similar way, the much-publicized report of the Institute of
Medicine, To Err is Human,38 describes an unhealthy United
States health care system. The report suggests regulation can
play a more significant role in public health protection, and that
problems with medication use are among the most significant
threats to quality in health care. The report concludes that al-
36. TROYEN BRENNAN & DONALD BERWICK, NEW RULES: REGULATION, MAR-
KETS AND THE QUALITY OF AMERICAN HEALTH CARE (1996).
37. Id. at 375-376.
38. See INSTITUTE OF MEDICINE, To ERR IS HUMAN: BUILDING A SAFER HEALTH
SYSTEM (1999).
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most all accidents in health care result from human error, and
these errors are usually induced by faulty systems that "set peo-
ple up" to fail. In order to learn from error, health care regula-
tors should require health care organizations to establish and
maintain environments and systems for analyzing accidents and
errors, so that redesign of processes is informed and
productive.39
B. Pharmacy Systems and the Internet
The absence of explicit design, lack of shared goals, and the
failure to use empirical evidence to correlate inputs with out-
puts, make it difficult to refer to medication use in the United
States as a "system." Non-systematic medication use by physi-
cians, pharmacists, and patients stands in stark contrast with the
highly systematic drug development, production, and distribu-
tion by pharmaceutical manufacturers. It is the lack of a system
that poses the greatest threat to quality in medication use, and
the potential of the Internet to provide the framework of a med-
ication use system is the greatest opportunity for responsive reg-
ulation of Internet pharmacy.
During new drug development, decisions about the safety and
efficacy of recently discovered molecules are made based on
randomized, controlled clinical trials that are evidence-based
and protocol-driven.4 0 Once approved for human use, the pro-
duction and distribution of pharmaceuticals is restricted by a re-
quirement for adherence to current Good Manufacturing
Practices ("cGMP"). 41 CGMPs mandate documentation, moni-
toring, and remediation when goals have not been met. The
value of this highly organized system early in the drug therapy
chain may be virtually nullified by the non-systematic last links
of the drug therapy chain, when actual medication use is based
on unguided, (and largely unevaluated) professional judgment,
along with misplaced faith that patients use their medications
appropriately and are satisfied with the results of their drug
therapy.
39. Id. at 155-201.
40. See 21 U.S.C.A. § 355(d) (West 1996) (mandating that sponsors of a new drug
show the drug to be safe and effective by "substantial evidence," which is defined as
"evidence consisting of adequate and well-controlled investigations, including clinical
investigations, by experts qualified . . . to evaluate the effectiveness of the drug
involved.").
41. 21 C.F.R. § 211.1 (2000).
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Problems associated with drug therapy have been widely at-
tributed to a need to re-engineer the system of medication use.
With pharmacists as the focal point of system change, federal
regulatory requirements have been initiated for Drug Regimen
Review in nursing homes, 42 and for a comprehensive program of
Drug Use Review aimed at outpatient pharmacy settings.43
Courts of law have begun to recognize that pharmacists have a
legal duty to evaluate drug therapy for every patient, and that
technical accuracy in order processing is necessary but not suffi-
cient to meet pharmacist professional responsibilities.4 State
boards of pharmacy have begun to shift their regulation from
structure and process only, to an emphasis on outcomes that are
linked to structure and process. 45 Mandatory CQI, as a compo-
nent of administrative regulation of pharmacies, has been
adopted by several states. 46 The pharmacy profession is emerg-
ing from its isolation on the street corners of the community and
the basements of hospitals to accept responsibility for system-
atizing medication use. A key component, that is lacking in
traditional medication use, is a means to facilitate communica-
tion among those who participate in medication use.
The Internet has the potential to be a key means of communi-
cation within a more systematic approach to drug therapy man-
agement. Two of the critical challenges to finding a solution to
the problem of inappropriate medication use are the inaccessi-
42. 42 C.F.R. § 483.60(c) (2000) (stating that drug regimen review requires that a
pharmacist examine all drugs being used by a nursing home resident at least once per
month, and evaluate the appropriateness of these drugs).
43. 42 U.S.C. § 1396r-8(g)(2)(A)(i) (1994) (mandating that drug use review re-
quires a pharmacist to screen each prescription for potential drug therapy problems,
and that if a potential problem is detected, it be resolved prior to dispensing the
medication).
44. Steven Huang, The Omnibus Budget Reconciliation Act of 1990: Redefining
Pharmacists' Legal Responsibilities, 24 AM. J. LAW & MED 417, 434 (1998) (noting the
drug use review requirements codify a pharmacist's common law duty to check pre-
scriptions for obvious errors, warn patients of known contraindications, and to warn
patients or reactions between prescription and non-prescription medications).
45. The current emphasis on outcomes linked to structure and process, rather than
structure and process by themselves, can be attributed to health services researcher
Avedis Donabedian, who was among the first to suggest that the true measure of
medical quality is the result of care. See Avedis Donabedian, Evaluating the Quality
of Medical Care, 44 MILBANK MEMORIAL FUND Q. 166 (1966).
46. A recent move by health care regulators to require continuous quality im-
provement programs as proactive prevention of problems for patients, rather than
using punishment of error as a reaction to problems for patients, has only begun to
catch the attention of the mainstream of health care regulation. See Troyen A. Bren-
nan, The Role of Regulation in Quality Improvement, 76 MILBANK Q. 709 (1998),
available at 1998 WL 13685934.
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bility of information describing the ideal for appropriate medi-
cation use and the deficiency of data defining the problems
experienced in actual medication use.47 Through the Internet,
physicians, pharmacists, and patients can access criteria and
standards for medication use, and they can develop strategies
for improving therapy to reflect evidence-based, consensus-de-
veloped, clinical practice guidelines. The Internet can host real-
time threaded discussions about therapy; some of which can be
open to all Internet users, others of which can be password pro-
tected for access only by health care providers. Patients can re-
port their symptoms, progress, and satisfaction with therapy on
the Internet.
For example, assume that a patient who has been diagnosed
with atrial fibrillation is treated with digoxin or another similar
drug.48 The patient is not prescribed an anticoagulant. Data
from drug studies with many patients indicate that of patients
diagnosed with atrial fibrillation, approximately 70% should be
treated with an anticoagulant. However, data also show that
only approximately 40% of the atrial fibrillation patients for
whom anticoagulation therapy is indicated actually receive this
beneficial therapy. By answering questions presented over the
Internet, patients for whom the therapy is indicated but who are
not receiving it can be identified and evaluated for anticoagula-
tion therapy. This evaluation can be facilitated by online access
to clinical practice guidelines. The questions asked of patients
can be prompted by the dispensing of digoxin, a marker drug for
atrial fibrillation. Once begun, anticoagulation therapy requires
close monitoring. The results of laboratory tests and other ob-
servations by the patient can be reported on the Internet, and
care providers can review this information to assure that stan-
dards for anticoagulation therapy are being met.
Not only can a health care provider use the Internet for the
benefit of individual patients, aggregated data can be uploaded
(with appropriate protection of patient confidentiality) to a cen-
47. See Jerry H. Gurwitz & Paula Rochon, Considerations in Designing an Ideal
Medication-Use System: Lessons from caring for the elderly, 57 AM. J. HEALTH-SYS.
PHARM. 548 (2000) (noting that information deficits are a key problem in medication
use, and that organized data systems can greatly facilitate demonstration projects de-
signed to improve the medication-use system).
48. Digoxin is frequently prescribed to improve the efficiency of the heartbeat.
The data used in this example should be considered as illustrative only. While the
example offered is a feasible one, constantly changing views of appropriate digoxin
use make it impossible to use completely reliable figures.
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tral location for analysis and use in generating new guidelines.49
For example, experience with the use of anticoagulants by pa-
tients who have been diagnosed with atrial fibrillation can be
reported to regulators and other reviewers for use as a perform-
ance database in the evaluation of a medication use system.
These are not advantages that affect only the relatively few ob-
vious beneficiaries in remote rural communities without ade-
quate health care services, they are benefits for all users of
medications, even those being treated at the most sophisticated
urban medical centers. By facilitating communication from
standards-setting groups, through health care professionals, to
patients; and back from patients, through health care profes-
sionals, to standards-setting groups, a comprehensive program
of medication use can be designed, with measurable goals and
with correlated inputs and outputs. The Internet can be the tool
through which medication use becomes a system.
The pharmacy is a logical focal point for an Internet-based
medication use system. Every pharmacy has a computer, unlike
other practice sites that may or may not be computerized, and
Internet-access is readily available in pharmacies. Formal alli-
ances between brick-and-mortar pharmacies and Internet phar-
macies have been established so that seamless provision of
pharmaceutical products and services between local and remote
practice sites is possible. Patients, their caregivers, and health
care providers can all log in to the pharmacy Internet site to
share information. Patients do not always go to the same physi-
cian for all medical needs, but they usually go to the same phar-
macy for their prescriptions. Thus, the pharmacy database is
likely to be the most up-to-date record of a patient's medication
use. When patients request refills of prescribed medications to
continue therapy at times when a visit to the physician need not
occur, valuable information about success or failure with drug
therapy, and satisfaction with drug therapy, can be elicited if the
appropriate questions are asked. Responses to these questions
are valuable data that can be used to close the quality loop be-
tween the providers of care and the recipients of care. Individ-
49. See Jeff Goldsmith, How Will the Internet Change Our Health System?; Power-
ful Though the Internet May Be, Its Impact on Health Care Will Continue to Be Tem-
pered by Privacy Concerns and Professional Resistence, 19 HEALTH AFF. 148 (2000)
(noting that the Internet brings to health care managers and clinicians a flexible, ex-
ternal information architecture that can reach down into the dozens, even hundreds,
of health care information "silos" and extract, analyze, aggregate, and redirect data,
which clinicians and managers can use to make decisions).
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ual patient responses that signal a need for medical attention
can be queued up for evaluation by a pharmacist and then for
referral to the patient's physician if necessary. Aggregated re-
sponses that indicate a common problem with many patients can
be referred to standards-setting organizations for review and
possible modification of practice guidelines.
III. ENABLING PATIENT RESPONSIBILITY FOR
DRUG THERAPY
The Internet does not increase the possibilities for pharma-
ceutical care; it increases the practicality of pharmaceutical care.
Any health-related activity that can be done electronically over
the Internet can also be done physically, within the traditional
medication use non-system. But the burdensomeness of physi-
cally looking up practice guidelines or interviewing patients
about outcomes from drug therapy makes it unlikely that these
activities will consistently be done without facilitation by the In-
ternet. Use of the Internet not only opens up possibilities for
enhanced communication up and down the chain of medication
use, it shifts the balance of power from providers of care to re-
cipients of care. The Internet changes the perspective of which
end is "up" in the chain of medication use.
Other advances in technology have had significant effects on
public participation in decisions about the use of products and
services. 50 The printing press made it possible to widely dissemi-
nate information, as did radio and television. Yet the informa-
tion disseminated through these media is controlled by the
provider. The active provider of information chooses what to
communicate to the passive recipient of information. The tele-
phone is qualitatively different, because it is interactive for in-
formation exchange, although the number of participants in
telephonic communication by voice is limited. By way of con-
trast, Internet users are active, their communication is interac-
tive, and the number of participants is almost limitless. Through
the Internet, the recipient of information has the opportunity to
select whatever source of information she or he chooses from
hundreds of thousands of possibilities. Internet users can inter-
act with each other, either on a real-time basis, or with only a
50. See Alissa R. Spielberg, Sociohistorical, Legal and Ethical Implications of E-
mail for the Patient-Physician Relationship, 280 JAMA 1353 (1998) (describing how
innovations in communication and transportation have generally been greeted with
initial concern, followed by relatively widespread acceptance).
[Vol. 10
20
Annals of Health Law, Vol. 10 [2001], Iss. 1, Art. 4
http://lawecommons.luc.edu/annals/vol10/iss1/4
Responsive Regulation of Internet Pharmacies
short delay. Recipients of information now control the message
they receive, due to Internet access. The Internet shifts the
power over information exchange from the provider of it to the
recipient of it.
A. Patient Autonomy and State Paternalism
A regulatory focus on providers of products and services
makes perfect sense when the providers control the dissemina-
tion of information about their products and services and when
providers can be readily located for enforcement activities.
However, since the Internet shifts the control of information
from providers to recipients, and since Internet providers are
difficult to locate, it makes better sense to focus regulation on
the recipients of Internet-based products and services. When
the products and services are pharmaceuticals, a shift in regula-
tory focus from health care providers to patients requires recon-
sideration of deeply held beliefs about public health protection
and about the need for centralized decision making about risk.
Within the traditional scheme of drug therapy regulation,
most decisions about risk are made for patients, and not with
patients. If a molecule has been discovered or synthesized, and
there is evidence indicating that the molecule might be useful as
a therapeutic agent, patients will nonetheless be denied the op-
portunity to use the molecule in their own therapy until years of
testing and data analysis show the molecule to be relatively safe
and effective for a population of users.51 Even after safety and
efficacy issues have been satisfactorily addressed and a new drug
is approved for human use, the new drug will likely be restricted
to "Rx Only" status. Only if a state-licensed prescriber then
gives permission will a patient be authorized to use this new
drug. While informed consent is a cornerstone of medical care
and of health care regulation, the concept is rarely applied to
drug therapy, and empirical data suggest patients are largely
uninvolved in the choice of their drug therapy. s2 Physicians de-
51. Despite the millions of dollars spent to study the safety and efficacy of new
drugs, approval does not in any way guarantee the adequacy of the pre-approval stud-
ies. See Barbara A. Noah & David B. Brushwood, Adverse Drug Reactions in Elderly
Patients: Alternative Approaches to Postmarket Surveillance, 33 J. HEALTH L. 383
(2000). The FDA has withdrawn approval of numerous drugs that have been shown
safe and effective with small numbers of subjects in controlled trials, yet have proven
to be unsafe and/or ineffective when used by large numbers of patients in therapeutic
use. Id.
52. Gerald F. Tietz, Informed Consent in the Prescription Drug Context: The Spe-
cial Case, 61 WASH. L. REV. 367 (1986) (suggesting that patients' rights, normally
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cide what drugs patients will use, and they prescribe how the
drugs will be used. Patients are given the choice of either fol-
lowing doctor's orders or developing their own medication use
behavior at the risk of being labeled as "noncompliant."53
Despite the emergence of a huge industry of alternative and/
or complementary therapies that circumvent this costly and dif-
ficult-to-access traditional system, the appropriateness of state
paternalism in drug therapy is seldom questioned. Drugs seem
complex and mysterious. They are known to be both injury-re-
ducing and injury-producing. It seems so sensible for govern-
ment to protect citizens from the bad choices they might make
in drug therapy, if given the opportunity to choose for them-
selves, even when only their own personal interests are at stake.
The reality that adverse drug effects are rampant within the cur-
rent paternalistic system of drug regulation is seldom considered
by those who challenge the notion that autonomous individuals
could make good drug therapy decisions for themselves if ena-
bled to do so.
In theory, restrictive regulation of drug therapy serves several
useful purposes: (1) it prevents overuse of drugs on which pa-
tients could become dependent, (2) it improves therapeutic out-
comes by assuring that patients receive therapy that will make
them better and not worse, (3) it brings patients back to physi-
cian offices on a consistent basis, so that necessary examinations
and tests can be routinely performed, (4) it protects the financial
resources of people who might otherwise squander their assets
on useless nostrums, and (5) it protects the community from
self-serving behaviors (i.e., antibiotic overuse) that are of lim-
ited value to individuals and are harmful to the population. 4
Each of these assertions is subject to challenge, particularly as
protected by the doctrine of informed consent, are not adequately protected when
patients receive prescription drug therapy); see also Jeremy Sugarman et al., Empiri-
cal Research on Informed Consent, An Annotated Bibliography, 29 HASTINGS CENTER
REP. S1 (1999) (listing and summarizing a long line of social science research that
documents a tradition of physician silence when prescribing medications, as opposed
to relatively well documented tradition of open disclosure by physicians when recom-
mending surgery).
53. See Jenny L. Donovan & David R. Blake, Patient Non-Compliance: Deviance
or Reasoned Decision-Making? 34 Soc. Sci. & MED. 507 (1992) (suggesting that pa-
tients who use medications differently from the way the medications have been pre-
scribed may be engaging in risk-benefit decision making outside the physician-patient
relationship).
54. See Chester N. Mitchell, Deregulating Mandatory Medical Prescription, 12 AM.
J. L. & MED. 207 (1986) (arguing that public safety needs do not justify the mandatory
prescription controls in place today).
[Vol. 10
22
Annals of Health Law, Vol. 10 [2001], Iss. 1, Art. 4
http://lawecommons.luc.edu/annals/vol10/iss1/4
Responsive Regulation of Internet Pharmacies
applied to a relatively sophisticated group of individuals, such as
those who use the Internet. It is not at all certain that users of
Internet pharmacy would act against their own self interest, or
against the interest of the community.
In response to those who paint a dire picture of potential
widespread tragedy resulting from anything other than consist-
ently aggressive and occasionally repressive regulation of In-
ternet pharmacy, it is perhaps equally as plausible to assert that
Internet users who are enabled to make good drug therapy deci-
sions for themselves would do so. Responsive regulation, as op-
posed to restrictive regulation, has the potential to increase the
availability of valid drug-related information and to facilitate as-
sistance with medical decisions made by patients through access
to online treatment algorithms.5 5 Responsive Internet regula-
tion could reduce health care costs and increase access to health
care. This is not a claim that such benefits necessarily would
result from responsive regulation of Internet pharmacy. The
only way to know whether appropriately enabled Internet users
could adequately protect themselves from harm caused by ad-
verse drug effects and produce benefits from available therapies
would be to compare outcomes in two populations: passive pa-
tients in the traditional system and active Internet users. In a
sense, Internet pharmacy could be seen as an experiment in pa-
tient autonomy. This may be the time to find out whether tech-
nically sophisticated medication users really need government
protection from themselves. This an opportunity for major in-
novation that should be taken seriously and empirically studied,
as are other experiments. The question is not whether Internet
pharmacy should be permitted; it is an unstoppable develop-
ment that is certain to increase in popularity. Regulators should
be asking how they can guide this inevitable technology through
regulation that appropriately protects and promotes the public
health.
B. Defining Relationships in Drug Therapy
The physician-patient relationship is one of the most highly
respected bonds in our society. It is a covenental relationship of
trust, which is based on an ideal of altruism and a reality of sci-
55. See Derek F. Meek, Telemedicine: How an Apple (Or Another Computer) May
Bring Your Doctor Closer, 29 CUMB. L. REv. 173 (1998) (describing the use of tech-
nology to increase access to care for those patients who are not close to their care
provider).
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entific complexity.5 6 There are special legal rules of confidenti-
ality, privilege, and duty that apply to this most important of
non-familial relationships. The medical profession has estab-
lished standards of practice that reflect questions not only of
technical expertise within the care provider role but also funda-
mental questions of role for the care provider. It is considered
beneath the standard of care for a physician to provide incom-
petent services or to provide competent services in an uncaring
way. The "what" and the "how" of medical care both matter.
Patients must feel comfortable in their relationship with their
physician, or else they will come to distrust the health care sys-
tem and refuse to participate in it - all to the detriment of indi-
viduals and the population.
Threats to the physician-patient relationship have been seen
in government oversight of the profession, as well as in corpo-
rate ownership of practice and in managed care.57 Interference
with the physician-patient relationship has even been used as
justification for restricting legal recognition of emerging ex-
panded responsibilities of pharmacists for drug therapy manage-
ment.58 Not unexpectedly, the Internet has been viewed with
suspicion by the medical establishment, fearful that electronic
communication could reduce the physician-patient relationship
to a physician-patient interface.5 9
Within other contexts, the medical profession has struggled to
define what activities of physicians comprise a satisfactory rela-
tionship with patients. For example, informed consent is now
considered a necessary prerequisite to surgery, and the elements
of a sufficient informed consent are generally well defined, al-
though they remain somewhat controversial. But informed con-
sent does not have a long history in medicine, and views persist
among some physicians that patients are better off not being in-
volved in complex medical decisions. 60 Drug therapy presents
different challenges for relationship definition because, unlike
56. Ranney V. Weisemann, On-Line or On-Call? Legal and Ethical Challenges
Emerging in Cybermedicine, 43 ST. Louis U. L. J. 1119 (1999) (noting that the essen-
tial feature of the physician-patient relationship is the exchange of a deep bond of
trust between the parties).
57. Id. at 1151.
58. See Lauren Fleischer, From Pill-Counting to Patient Care: Pharmacists' Stan-
dard of Care in Negligence Law, 68 FORDHAM L. REV. 165 (1999) (arguing that phar-
macist consultations with physicians and patients actually enhance the physician-
patient relationship rather than threatening that relationship).
59. See Spielberg, supra note 50, at 1359.
60. See JAY KATZ, THE SILENT WORLD OF DocTOR AND PATIENT (1984).
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surgery, there is no requirement that a "touching" occur for a
physician to provide pharmaceutical treatment. The natural re-
quirement for physical proximity in surgery need not logically
lead to the human imposition of such a requirement in drug
therapy. Physical proximity of physician and patient, of a type
that will permit a hands-on examination prior to authorization
to use any medication, seems unnecessary under all
circumstances.
When a physician knows a patient already, or when a patient
is known to another physician within a practice, and documenta-
tion of impressions from earlier care is readily available in a pa-
tient care record, it is not always necessary for the patient to
physically visit a physician. Forcing a patient who is physically
incapacitated or who has significant transportation barriers to
visit a physician to secure permission to continue treatment of a
recurrent or chronic condition seems wasteful of resources and
unnecessarily inconvenient. On the other hand, a physician's
brief review of a checklist submitted by a patient hundreds or
thousands of miles away clearly cannot create a new physician-
patient relationship within the model for practice that the medi-
cal establishment has developed. The difficult challenge is
knowing how much physician-patient contact is enough for safe
and effective treatment, and how much is too burdensome for
patients who will forego all treatment when barriers to access
are overwhelming. The inevitable conclusion is that one-size-
fits-all descriptions of activities that comprise a sufficient physi-
cian-patient relationship, from a medical perspective, will fail to
accommodate individual patient differences and varied personal
circumstances.
The difficulty of using a medical model to define the character
of a sufficient physician-patient relationship raises the possibility
that other models might be more useful, including perhaps a pa-
tient-centered model. A sufficient physician-patient relation-
ship might be one the patient believes to be sufficient, based on
whatever criteria the patient chooses to apply. Deference to pa-
tients as the arbiters of the sufficiency of their relationship with
physicians would require trusting patients to act responsibly on
behalf of themselves and the community. Reliance on patients
to make this determination could be based on respect for indi-
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vidual autonomy, a basic principle of biomedical ethics.61 The
market failure of information asymmetry, which is often cited to
justify state paternalism in drug therapy, may not be a persua-
sive rationale when applied to patients who are able to use the
Internet and have access to virtually limitless information.62
There is always the question of individual liberty and the chal-
lenge a free society must face in justifying any choice of the risks
from which its members will be protected by government. It is
difficult to understand why people can be allowed to eat snack
foods with no nutritional value, participate in hazardous sport-
ing events, and elect whomever they wish to govern them, but
not be allowed to choose their own medicine. This observation
is not intended to be an absolute claim that all patients could
always appropriately define their relationship with a physician,
but it is a suggestion that those who advocate strong regulation
of Internet pharmacy in ways that perpetuate traditional physi-
cian-patient relationships should explain the basis of their advo-
cacy. It may well be that harm resulting from a decision by a
well-informed Internet user to acquire medication without med-
ical authority should not be viewed as a regulatory failure.
C. Operationalizing Patient Responsibility
Conceptualizing and describing an ideal of informed and ra-
tional drug therapy choice by Internet pharmacy users is easier
than is putting this laudable goal into practice. Responsible use
of Internet pharmacy requires that users know the choices avail-
able to them and reflect on the consequences of their choices
before they engage in potentially risky behaviors. Users of In-
ternet pharmacies need to know significant therapeutic aspects
of the medications they consider using. They also need to know
the identity and qualifications of those from whom they acquire
medications. If they choose to take risks with medications, or to
acquire medications from unreliable or unidentified sources,
then they must understand that protections ordinarily provided
by regulatory agencies are being foregone.
The only means yet developed to enable Internet pharmacy
users to protect themselves from risks that are unacceptable to
61. See Charity Scott, Why Law Pervades Medicine: An Essay on Ethics in Health
Care, 14 NOTRE DAME J.L. ETHICS & PUB. POL'Y 245 (2000) (discussing the close
relationship between law and ethics).
62. See Eyal Zamir, The Efficiency of Paternalism, 84 VA. L. REV. 229 (1998)
(containing an economic analysis of general legal paternalism).
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them is the VIPPS program established and operated by
NABP.63 VIPPS is a voluntary program. Internet pharmacy
sites that opt for VIPPS certification must apply to the NABP.
The application is reviewed by NABP to assure that the Internet
pharmacy is in compliance with relevant state and federal laws.
VIPPS pharmacies must also maintain a quality assurance or
quality improvement program. They must report to NABP any
changes of information provided as part of the initial certifica-
tion process. Once issued, certification is renewable annually
following an update of the registration information and re-ver-
ification of licensure status.
VIPPS certified Internet pharmacies are granted authority to
use the NABP/VIPPS hyperlink seal on their web sites. Visitors
to the site may click on the seal to receive real-time verification
that the site is certified. Any site that pirates the "click to ver-
ify" seal will soon discover the online, real-time verification pro-
cess does not work for any site other than the certified site.
"Rogue" sites are immediately exposed to the Internet user.
Through the VIPPS program, Internet pharmacy users receive
assurance that their certified provider has met exacting quality
standards. They know who is providing their pharmaceutical
products and services, and to whom to complain when things
have not gone well. Although VIPPS is not a regulatory pro-
gram, it provides assurance to Internet pharmacy users that cer-
tified sites are being overseen by pharmacy regulators.
The most significant drawback of VIPPS is that it is not well
known to Internet pharmacy users. Even the best program is of
little value if those who would benefit from it do not know
about it. Pharmacy regulators should feel comforted that they
have made significant strides toward adequately protecting the
public health by endorsing and participating in the VIPPS pro-
gram. However, until public knowledge of VIPPS increases to
the level of, for example, the Good Housekeeping Seal of Ap-
proval or the Consumer Reports product ratings, there will con-
tinue to be significant regulatory challenges to meet in Internet
pharmacy. Fortunately, there is a readily available medium to
use in getting the word out about VIPPS to Internet pharmacy
users; that medium is the Internet itself. By requiring search
engines to provide streaming cautionary statements to any In-
ternet user who enters a search term that suggests the intent to
63. A full description of the VIPPS program can be found at the VIPPS web site,
at <www.nabp.net/vipps/intro.asp> (last visited Mar. 26, 2001).
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acquire prescription-only drugs over the Internet, the user who
is uninformed about VIPPS has the opportunity to discover the
protections this program provides. It might be possible to re-
quire this same streaming cautionary statement be displayed any
time an Internet user enters a Uniform Resource Locator
("URL") with similarly suggestive terms. The objective would
not be to forbid use of the Internet, but to inform users that they
may be going to a site where the presence or absence of the
VIPPS seal would be a significant factor for them. Some In-
ternet pharmacy users would continue to use sites not certified
by the VIPPS program, but only after being informed of the
VIPPS program and making a conscious choice to forego the
protection it provides.
CONCLUSION
Traditional enforcement-oriented regulation will continue to
have a role to play in government oversight of Internet phar-
macy, when the pharmacy can be physically located, when re-
sources necessary for enforcement are available, and when
enforcement does not have a chilling effect on beneficial
telehealth activities. However, it would seem sensible to stew-
ard scarce regulatory resources and devote them primarily to
enforcement directed at those who distribute addictive con-
trolled substances, or highly toxic drugs, to users who have or-
dered them over the Internet. Interfering with the acquisition of
hair restoratives or drugs intended to enhance sexual function is
an exercise of state paternalism that goes beyond what is neces-
sary or expected under the circumstances. To be successful, any
regulatory agency has to be credible with the public it serves,
and the targeting of "lifestyle" drugs has the potential to ad-
versely affect the credibility of pharmacy regulators. Mounting
a taxpayer-funded crusade against bad choices that adversely af-
fect nobody other than the person making the choice could have
the appearance of economic protectionism, no matter how well
intended as a public health measure.
Regulation of Internet pharmacy to protect the public health
will be most effective when it empowers Internet users to pro-
tect themselves from risks the users believe to be unacceptable.
Promotion of the VIPPS program is the best assurance regula-
tors can provide to the public that individual Internet pharmacy
users are being protected by the professionalism that state-li-
censed pharmacists offer through their oversight of the medica-
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tion use process. Pharmaceutical care can be made more
successful through Internet alliances within pharmacy; and be-
tween pharmacists, physicians and patients. In the end, this is
simply a matter of trusting people to make good choices for
themselves and providing them with the means to make their
choices as good as they can be.
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